Premium
Comparative effects of teriparatide and risedronate in glucocorticoid‐induced osteoporosis in men: 18‐month results of the EuroGIOPs trial
Author(s) -
Glüer ClausC,
Marin Fernando,
Ringe Johann D,
Hawkins Federico,
Möricke Rüdiger,
Papaioannu Nikolaos,
Farahmand Parvis,
Minisola Salvatore,
Martínez Guillermo,
Nolla Joan M,
Niedhart Christopher,
Guañabens Nuria,
Nuti Ranuccio,
MartínMola Emilio,
Thomasius Friederike,
Kapetanos Georgios,
Peña Jaime,
Graeff Christian,
Petto Helmut,
Sanz Beatriz,
Reisinger Andreas,
Zysset Philippe K
Publication year - 2013
Publication title -
journal of bone and mineral research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.882
H-Index - 241
eISSN - 1523-4681
pISSN - 0884-0431
DOI - 10.1002/jbmr.1870
Subject(s) - teriparatide , osteoporosis , medicine , glucocorticoid , endocrinology , bone mineral
ABSTRACT Data on treatment of glucocorticoid‐induced osteoporosis (GIO) in men are scarce. We performed a randomized, open‐label trial in men who have taken glucocorticoids (GC) for ≥3 months, and had an areal bone mineral density (aBMD) T ‐score ≤ –1.5 standard deviations. Subjects received 20 μg/d teriparatide ( n = 45) or 35 mg/week risedronate ( n = 47) for 18 months. Primary objective was to compare lumbar spine (L 1 –L 3 ) BMD measured by quantitative computed tomography (QCT). Secondary outcomes included BMD and microstructure measured by high‐resolution QCT (HRQCT) at the 12th thoracic vertebra, biomechanical effects for axial compression, anterior bending, and axial torsion evaluated by finite element (FE) analysis from HRQCT data, aBMD by dual X‐ray absorptiometry, biochemical markers, and safety. Computed tomography scans were performed at 0, 6, and 18 months. A mixed model repeated measures analysis was performed to compare changes from baseline between groups. Mean age was 56.3 years. Median GC dose and duration were 8.8 mg/d and 6.4 years, respectively; 39.1% of subjects had a prevalent fracture, and 32.6% received prior bisphosphonate treatment. At 18 months, trabecular BMD had significantly increased for both treatments, with significantly greater increases with teriparatide (16.3% versus 3.8%; p = 0.004). HRQCT trabecular and cortical variables significantly increased for both treatments with significantly larger improvements for teriparatide for integral and trabecular BMD and bone surface to volume ratio (BS/BV) as a microstructural measure. Vertebral strength increases at 18 months were significant in both groups (teriparatide: 26.0% to 34.0%; risedronate: 4.2% to 6.7%), with significantly higher increases in the teriparatide group for all loading modes (0.005 < p < 0.015). Adverse events were similar between groups. None of the patients on teriparatide but five (10.6%) on risedronate developed new clinical fractures ( p = 0.056). In conclusion, in this 18‐month trial in men with GIO, teriparatide showed larger improvements in spinal BMD, microstructure, and FE‐derived strength than risedronate.